GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (2)
  • Koo, Ja Seung  (2)
Material
Publisher
  • American Association for Cancer Research (AACR)  (2)
Person/Organisation
Language
Years
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Abstract C10: Class III β -tubulin predicts pathological response to neoadjuvant docetaxel-based chemotherapy in breast cancer patients.
    American Association for Cancer Research (AACR) ; 2011
    In:  Molecular Cancer Therapeutics Vol. 10, No. 11_Supplement ( 2011-11-12), p. C10-C10
    Details
    In: Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 10, No. 11_Supplement ( 2011-11-12), p. C10-C10
    Abstract: Background: Class III β-tubulin has been suggested as a potential predictor of taxane response for several cancers including breast cancer, although controversies exist. We evaluated correlations between class III β-tubulin and docetaxel response in neoadjuvant setting of breast cancer, focusing on pathological response which is considered the most powerful predictor of outcome. Materials and Methods: Fifty-five patients with primary breast cancer who had undergone neoadjuvant doxetaxel and adriamycin were included in this study. Class III β-tubulin was measured by immunohistochemistry in prechemotherapy paraffin-embedded tumor tissues. The cutoff value of ‘high’ and ‘low’ expression of class III β-tubulin was set at 50% of tumor cell staining. ‘Good pathological response’ was defined by pathological complete response (pCR) or microscopic residual disease (i.e., breast tumor ≤1cm and negative axillary node). The counterpart was designated as ‘poor pathological response’. Results: Before chemotherapy, 14 patients were in clinical stage II and 41 were in clinical stage III. After the median 4 cycles of preoperative chemotherapy, clinical downstaging was observed in 40 patients whereas clinical staging did not change in the remaining patients. Eleven patients (20%) showed good pathological response (pCR, 6; microscopic residual disease, 5) and 44 (80%) showed poor pathological response. Thirty-six (65.5%) and 19 patients (34.5%) were categorized into low and high class III β-tubulin groups, respectively. Low class III β-tubulin was associated with low histologic grade (P=0.052). However, in multivariate logistic regression adjusted by known prognostic factors including histologic grade, low expression of class III β-tubulin (hazard ratio = 11.1; P = 0.049) and triple negative status (hazard ratio = 6.86; P = 0.022) were independent predictors of good pathological response. At the median follow-up of 40.8 months after surgery, recurrence occurred in 11 patients (5 in low class III β-tubulin group; 6 in high). Low expression of class III β-tubulin showed a favorable risk of relapse (P=0.152) which did not reach statistical significance probably due to short follow-up period. Conclusions: Low expression of class III β-tubulin by immunohistochemistry predicts good pathological response to neoadjuvant docetaxel in breast cancer, suggesting implications for improving chance to define docetaxel-beneficial group in this setting. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C10.
    Type of Medium: Online Resource
    ISSN: 1535-7163 , 1538-8514
    URL: Article
    DOI: 10.1158/1535-7163.TARG-11-C10
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2062135-8
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Abstract 3897: A difference of HER-2 amplification index between luminal B and HER2 enriched subgroup
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Research Vol. 71, No. 8_Supplement ( 2011-04-15), p. 3897-3897
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 3897-3897
    Abstract: Background: The aim of this study was to compare the HER2 gene amplification index (AI) of luminal B and HER-2 enriched breast cancers using fluorescence in situ hybridization (FISH). Methods: Out of 753 patients with breast cancer who were tested HER2 status by FISH between Jan 2004 to Dec 2009, 224 HER2 amplified patients were available for this study. HER2-amplified breast cancers constitute a heterogenous group that may be subdivided according to their ER status: HER2 amplified ER-positive breast carcinomas that fall into the luminal B group; and HER2 amplified ER-negative cancers which form a distinct molecular subtype, known as the HER2 enriched group according to hormone status by immunohistochemistry and HER2 amplification confirmed as HER2/CEP17 ratio by FISH. A difference of HER2 AI was analyzed between luminal B and HER-2 enriched group. Clinicopathologic parameters were analyzed. Results: Among the HER2 amplified patients, the proportion of luminal B and HER2 breast cancer was 53.5% (N=120) and 46.5% (N=104), respectively. Early breast cancer patients were 84.8% (N=190) and metastatic breast cancer patients were 15.2% (N=34). HER-2 AI of luminal B group and HER2 enriched group were 4.99 and 5.84 respectively, which values showed the quantitative difference statistically significant (p=0.003). However, increasing value of HER2 AI was not associated with a better overall survival or progression free survival. In luminal B group, a significant difference of HER2 AI between ER/PR +/+ subgroup and ER/PR +/- subgroup existed which were 4.02 and 5.32, respectively (p=0004). Conclusions: The HER2 AI of HER2 enriched group was higher than that of luminal B group statistically significant. It was not clear whether the extent of HER-2 amplification relates to the survival benefit of treatment in HER-2 positive breast cancer. Further research to understand how the level of HER2 amplification is related to prognosis is warranted in order to understand the breast cancer biology associated with the intrinsic subtypes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3897. doi:10.1158/1538-7445.AM2011-3897
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2011-3897
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...